Hemorrhagic cystitis (HC) is an important complication after hematopoietic stem cell transplantation (HSCT). 1 The severity varies from microscopic hematuria to severe hemorrhage leading to clot retention and urinary tract obstruction. Based on the temporal relationship to HSC engraftment, HC can be divided into pre-and postengraftment subtypes. 2 Pre-engraftment HC is related to urothelial toxicity induced by chemo-irradiation during conditioning. It is usually transient, with an incidence similar in both autologous and allogeneic HSCT. 2 On the contrary, post-engraftment HC is a major complication and a common cause of prolonged hospitalization after allogeneic HSCT.
The pathogenesis of post-engraftment HC is not well defined. Reactivation of human polyoma BK virus (BKV) leading to BK viruria is a distinct risk factor. 2, 3 We have demonstrated that post-engraftment HC is invariably preceded by a peaking in BK viruria. 3 However, not all patients with BKV reactivation develop HC, suggesting that additional pathogenetic factors are involved. Furthermore, most cases of post-engraftment HC have been found in allogeneic HSCT, in the presence of graft-versus-host diseases (GVHD). 1, 2, 4 To segregate the impacts of BKV reactivation and allo-immunity on post-engraftment HC, we studied a cohort of patients after autologous HSCT, where allo-immunity would not be a confounding factor.
Consecutive patients who underwent autologous HSCT in Queen Mary Hospital, Hong Kong, were studied prospectively. For patients receiving conditioning with cyclophosphamide, prophylaxis against HC included forced diuresis and the administration of MESNA (2-mercaptoethane sulfonate) prior to and until the last dose of cyclophosphamide. All patients were given acyclovir (5 mg/kg every 8 h) for prophylaxis against herpes simplex infection, from the commencement of conditioning to 30 days after HSCT. None of them had received ganciclovir or cidofovir.
Urinary BKV quantification by real-time quantitative polymerase chain reaction (Q-PCR) was performed as described. 3, 5 Briefly, 24 h urine was collected before the commencement of conditioning, on the day of HSC infusion (day 0) and weekly thereafter until day 42. DNA was extracted from 200 ml of free urine, which had a higher BKV load than urinary sediments, 5 by the QIAamp Blood Minikit (Qiagen, Basel, Switzerland). BKV Q-PCR was performed by the ABI Prism 7700 Sequence Detector (PE Biosystems, Foster City, CA, USA) by an operator blinded to the clinical details of the patients. Sequences of the Q-PCR primers and TaqMan probe (targeting the BKV VP1 gene), amplification protocols, PCR precautions and quality assurance have been described. 5 Results were expressed as median values unless otherwise stated. Comparison between categorical data was evaluated by Pearson w 2 test, and between numerical data by MannWhitney U test (SPSS 11.5 Chicago, IL, USA). P-values of o0.05 were considered significant.
In total, 11 patients were studied. The median age was 43 (24-67) years. The underlying hematologic diseases and their corresponding conditioning regimens were nonHodgkin's lymphoma/cyclophosphamide-BCNU-etoposide (n ¼ 5), multiple myeloma/melphalan (n ¼ 4), and Hodgkin's lymphoma/BCNU-etoposide-cytarabine arabinoside-melphalan (n ¼ 2).
The median BK viruria before conditioning was 1.8 Â 10
) copies/ml. After HSCT, two patterns of BK viruria were observed. Four patients (36.4%) exhibited a significant increase (defined as X10 ) copies/ml (Figure 1b) . A comparison with 68 patients after allogeneic HSCT 5 showed that the pattern and degree of BK viruria were comparable (Table 1) . However, post-engraftment HC only occurred in patients after allogeneic HSCT, and not in any patient after autologous HSCT.
In this study, BKV reactivation occurred frequently in patients after autologous HSCT. Furthermore, when the magnitude, pattern and timing of BK viruria were considered, patients after autologous HSCT were remarkably similar to those after allogeneic HSCT. We have shown in previous studies that a significant (X3 log) peaking of BK viruria was a pre-requisite for post-engraftment HC in allogeneic HSCT. 3 Furthermore, in 68 patients after allogeneic HSCT where BKV was quantified with a similar protocol, 29 (43%) showed peaking of BK viruria, of whom eight developed post-engraftment HC. 3 In this series of patients after autologous HSCT, peaking of BK viruria also occurred at a comparable frequency. However, none of the patients after autologous HSCT developed post-engraftment HC. Although the relatively small number of patients in this study makes a definitive comparison between allogeneic and autologous HSCT difficult, the importance of allo-immunity in post-engraftment HC has also been shown in previous studies involving larger number of patients, where HC was significantly more frequent in allogeneic as compared with autologous HSCT. 1, 6 Therefore, BK viruria appears to be necessary but not sufficient for the development of post-engraftment HC, and alloreactivity may be an important contributing factor. This premise requires validation by larger number of patients.
These observations allow us to propose a putative model of post-engraftment HC. The myeloablative conditioning regimen damages the uroepithelium. The ensuing uroepithelial regeneration leads to active cell division, providing a milieu for BKV reactivation to occur during the immunosuppression resulting from the HSCT. Upon engraftment and return of immunocompetence, uroepithelial cells infected with BKV, which may express BKV antigens, 7 become targets for recovering immune cells. In support of this proposition, BKV associated HC has occurred in patients infected with the human immunodeficiency virus, but only when the CD4 þ lymphocyte count has risen after effective antiviral treatment. 8 When this immune attack is further heightened in conjunction with allo-immunity against transplantation antigens, as occurs in GVHD in the setting of allogeneic HSCT, severe HC develops. 9 This model may explain why similar reactivation of BKV in both autologous and allogeneic HSCT leads to HC preferentially in the latter situation. Therefore, postengraftment HC is reminiscent of immunorestitution disease, 10 where acute symptomatic deterioration of a preexisting infection occurs on recovery of the immune system. This model generates hypotheses that can be tested clinically, including the impact of conditioning intensity on BK viruria, the suppression of BKV replication in preventing HC, and the use of immunosuppression in the treatment of post-engraftment HC. Road, Hong Kong; and 
